# Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

> **NCT04798781** · PHASE2 · COMPLETED · sponsor: **Andrew Hendifar, MD** · enrollment: 16 (actual)

## Conditions studied

- Gastric Cancer
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Telatinib
- **DRUG:** Keytruda

## Key facts

- **NCT ID:** NCT04798781
- **Lead sponsor:** Andrew Hendifar, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-28
- **Primary completion:** 2024-02-14
- **Final completion:** 2025-10-20
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04798781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04798781, "Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04798781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*